[儿童肉瘤] 儿童肉瘤
1Abteilung für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Tübingen, Hoppe-Seyler-Straße 3, 72076, Tübingen, Deutschland. ilias.tsiflikas@med.uni-tuebingen.de.
Radiologie (Heidelberg, Germany)
|February 10, 2026
概括
精确的成像对于儿童肉瘤预后至关重要. 像扩散权重MRI和PET/MRI这样的先进技术为分期和后期护理提供了低辐射的替代方案,改善了治疗结果.
科学领域:
- 儿科瘤学 儿科瘤学
- 医学成像医学成像
- 放射学 放射学是一门学科.
背景情况:
- 儿科瘤是罕见的,侵略性的,异质的瘤,需要精确的成像来准确的预后.
- 成长中的儿童复杂的解剖学需要专门的成像协议,以有效地分阶段和治疗计划.
研究的目的:
- 突出先进的成像技术在儿童肉瘤的诊断,分期和管理中的重要作用.
- 讨论区分残留瘤,复发和治疗后变化的挑战.
- 强调标准化协议和跨学科合作的重要性.
主要方法:
- 磁共振成像 (MRI) 使用儿科协议 (视野小,薄片) 是局部分期的黄金标准.
- 超声波用于初级诊断和活检计划.
- 低剂量胸部计算机断层扫描 (CT) 评估肺转移.
- 扩散权重核磁共振和正电子发射断层扫描 (PET) /核磁共振为全身分级提供低辐射替代方案.
主要成果:
- 影像精确地划分神经血管结构和生长板,这对于节约四肢手术至关重要.
- 区分重要的残留瘤,复发和治疗后的变化仍然是一个挑战.
- 标准化的协议和跨学科的整合是成功治疗概念的关键.
结论:
- 像扩散权重MRI和PET/MRI这样的先进成像模式对于儿科肉瘤分期和后期护理非常有价值.
- 标准化方案的一致应用和放射学,瘤学和外科之间的跨学科合作对于最佳的患者结果至关重要.
相关概念视频
Rous Sarcoma Virus (RSV) and Cancer
6.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
6.4K
Pharmacokinetics in Pediatric Patients: Drug Excretion
274
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
274
Pharmacokinetics in Pediatric Patients: Drug Distribution
330
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
330
Pharmacokinetics in Pediatric Patients: Drug Metabolism
245
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
245
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
307
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
307


